



## Claims

1. A method for obtaining direct dilatation of the coronary arteries  
 5 comprising administering to a mammal in need thereof a therapeutically effective amount of a phospholamban inhibitor.
2. A method for the treatment of coronary heart disease comprising administering to a mammal in need thereof a therapeutically effective amount of a phospholamban inhibitor.
- 10 3. A method for the treatment of hemodynamic crisis in which the low aortic blood pressure decreases coronary perfusion pressure comprising administering to a mammal in need thereof a therapeutically effective amount of a phospholamban inhibitor.
4. Compounds of formula (I) or (II):



in which

- R<sub>1</sub> is hydrogen, alkyl, alkenyl, aryl, arylalkyl, hydroxyalkyl, halogenalkyl, alkoxy, COR<sub>10</sub>, CONR<sub>10</sub>R<sub>11</sub>, OR<sub>10</sub>, S(O)<sub>m</sub>R<sub>10</sub>, NR<sub>10</sub>COR<sub>11</sub> or NR<sub>10</sub>R<sub>11</sub>, where R<sub>10</sub> is hydrogen, alkyl, alkenyl, aryl, arylalkyl, hydroxyalkyl, halogenalkyl, alkoxy or hydroxy and R<sub>11</sub> is hydrogen, alkyl, aryl, arylalkyl, alkoxy, aryloxy, hydroxy or acyl, or in case where X is NR<sub>11</sub>, can R<sub>1</sub> also be carboxylalkyl,
- 20

R<sub>6</sub> is hydrogen, alkyl, alkenyl, aryl, arylalkyl,

R<sub>2</sub> and R<sub>7</sub> mean hydrogen, alkyl, aryl, arylalkyl, alkenyl, COR<sub>10</sub>, CONR<sub>10</sub>R<sub>11</sub>, halogen, trifluoromethyl, nitro or cyano, where R<sub>10</sub> and R<sub>11</sub> are defined as above,

R<sub>3</sub> is hydrogen, alkyl, aryl or arylalkyl,

5 A means alkyl or substituted alkyl,


m is 0-2 and n is 1-3,

Y means O, NR<sub>11</sub> or S, where R<sub>11</sub> is the same as above,

X means O, NR<sub>11</sub> or S, where R<sub>11</sub> is the same as above,

R<sub>4</sub>, R<sub>5</sub>, R<sub>8</sub> and R<sub>9</sub> mean independently one of the following groups:

10



15

or in case where X is NR<sub>11</sub>, can R<sub>4</sub>, R<sub>5</sub>, R<sub>8</sub> and R<sub>9</sub> also independently mean HOOC-, R<sub>12</sub>OOC-, H<sub>2</sub>NCO- or HOHNCO-, wherein R<sub>12</sub> means alkyl, arylalkyl or aryl,

and wherein each aryl residue defined above by itself or as part of another group may be substituted,

20

and pharmaceutically acceptable salts and esters thereof.

5. A compound of claim 4 wherein said compound has formula (I) and R<sub>2</sub> is hydrogen.

6. A compound of claim 5 wherein R<sub>1</sub> is hydrogen, C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>6-10</sub> aryl, C<sub>7-12</sub> arylalkyl, C<sub>1-6</sub> hydroxyalkyl, C<sub>1-6</sub> halogenalkyl or C<sub>1-6</sub> alkoxy.

25

7. A compound of claim 6 wherein Y is O or S, and X is O.

30


8. A compound of claim 6 wherein Y is O or S; and X is NR<sub>11</sub>, where R<sub>11</sub> is hydrogen, C<sub>1-6</sub> alkyl, C<sub>6-10</sub> aryl, C<sub>7-12</sub> arylalkyl, C<sub>1-6</sub> alkoxy, C<sub>6-10</sub> aryloxy, hydroxy, C<sub>1-6</sub> alkanoyl or C<sub>1-6</sub> carboxyalkyl.

9. A compound of claim 8, wherein R<sub>3</sub> is hydrogen, C<sub>1-6</sub> alkyl, C<sub>6-10</sub> aryl, or C<sub>7-12</sub> arylalkyl.

10. A compound of claim 9, wherein R<sub>3</sub> is C<sub>1-6</sub> alkyl.

11. A compound of claim 10, wherein A is straight-chain or branched C<sub>1-4</sub> alkylene and R<sub>4</sub> and R<sub>5</sub> are each

35



5

; or where X is NR<sub>11</sub>, then R<sub>4</sub> and R<sub>5</sub> can also be HOOC-, R<sub>12</sub>OOC-, H<sub>2</sub>NCO- or HOHNCO-, where R<sub>12</sub> is C<sub>1-6</sub> alkyl, C<sub>6-10</sub> aryl, or C<sub>7-12</sub> arylalkyl.

12. A compound of claim 4, wherein said compound has formula (II) and R<sub>7</sub> is hydrogen.

13. A compound of claim 12, wherein R<sub>6</sub> is hydrogen, C<sub>1-6</sub> alkyl, C<sub>6-10</sub> aryl, C<sub>7-12</sub> arylalkyl; and n is 1, 2 or 3.


14. A compound of claim 13, wherein Y is O or S, and X is O.

15. A compound of claim 13, wherein Y is O or S; and X is NR<sub>11</sub>, where R<sub>11</sub> is hydrogen, C<sub>1-6</sub> alkyl, C<sub>6-10</sub> aryl, C<sub>7-12</sub> arylalkyl, C<sub>1-6</sub> alkoxy, C<sub>6-10</sub> aryloxy, hydroxy, C<sub>1-6</sub> alkanoyl or C<sub>1-6</sub> carboxyalkyl.

16. A compound of claim 14, wherein A is straight-chain or branched C<sub>1-4</sub> alkylene.

17. A compound of claim 16, wherein R<sub>4</sub> and R<sub>5</sub> are each

20



25

; or where X is NR<sub>11</sub>, then R<sub>4</sub> and R<sub>5</sub> can also be HOOC-, R<sub>12</sub>OOC-, H<sub>2</sub>NCO- or HOHNCO-, where R<sub>12</sub> is C<sub>1-6</sub> alkyl, C<sub>6-10</sub> aryl, or C<sub>7-12</sub> arylalkyl.


18. A pharmaceutical composition comprising a compound of claim 4 as an active ingredient together with pharmaceutically acceptable carrier.

30

19. A method of treating heart failure comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 4.

20. A method for the treatment and prevention of stunned myocardium comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1.

21. A compound of formula (XXV):



15        wherein R<sub>1</sub> is hydrogen, alkyl, alkenyl, aryl, arylalkyl, hydroxyalkyl, halogenalkyl, alkoxy, COR<sub>10</sub>, CONR<sub>10</sub>R<sub>11</sub>, OR<sub>10</sub>, S(O)<sub>m</sub>R<sub>10</sub>, NR<sub>10</sub>COR<sub>11</sub> or NR<sub>10</sub>R<sub>11</sub>, where R<sub>10</sub> is hydrogen, alkyl, alkenyl, aryl, arylalkyl, hydroxyalkyl, halogenalkyl, alkoxy or hydroxy and R<sub>11</sub> is hydrogen, alkyl, aryl, arylalkyl, alkoxy, aryloxy, hydroxy or acyl, or carboxylalkyl,

20        R<sub>3</sub> is hydrogen, alkyl, aryl or arylalkyl,  
           R<sub>11</sub> is hydrogen, alkyl, aryl, arylalkyl, alkoxy, aryloxy, hydroxy or acyl, or carboxylalkyl,

          and wherein each aryl residue defined above by itself or as part of another group may be substituted.